help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Venihaki, M.
Right arrow Articles by Margioris, A. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Venihaki, M.
Right arrow Articles by Margioris, A. N.
Endocrinology Vol. 138, No. 2 698-704
Copyright © 1997 by The Endocrine Society


Articles

Comparative Study between Normal Rat Chromaffin and PC12 Rat Pheochromocytoma Cells: Production and Effects of Corticotropin-Releasing Hormone1

Maria Venihaki, Achille Gravanis and Andrew N. Margioris

Departments of Clinical Chemistry and Pharmacology, School of Medicine, University of Crete, Iraklion, GR-711 10, Crete, Greece

Address all correspondence and requests for reprints to: Andrew N. Margioris, Department of Clinical Chemistry, School of Medicine, University of Crete, Iraklion, GR-711 10, Crete, Greece. E-mail: andym{at}med.uch.gr


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The adrenal medulla of several species and some human pheochromocytomas contain CRH. The first aim of the present work was to find out whether normal rat adrenal chromaffin cells and the PC12 rat pheochromocytoma cell line produce CRH in vitro and what regulates its production. CRH was measured and characterized in the media of both types of chromaffin cells under basal conditions and after exposure to K+, nicotine, interleukin-1ß, and nerve growth factor (NGF). The second aim was to examine the biological effect of exogenous CRH (and of its antagonist) on the production of catecholamines from these two types of cells. Our results are as follows: 1) Both types of chromaffin cells contained and secreted comparable amounts of immunoreactive-CRH under basal conditions and after K+-induced depolarization, nicotine, and interleukin-1ß; 2) the physicochemical characteristics of the immunoreactive-CRH in the cells and the media were identical to the putative CRH peptide on both sieve chromatography and RP-HPLC; 3) synthetic CRH induced the production of catecholamines from both cell types in a dose- and time-dependent manner; this effect was abolished by the antagonist, {alpha} helical CRH; 4) exposure of PC12 cells to NGF (for 1 week) resulted in their neuronal differentiation and the stimulation of their production of CRH by 30 times and of dopamine by 10 times, compared with parallel controls; this effect of NGF was abolished by {alpha} helical CRH. In conclusion, our data suggest that the production of CRH by PC12 cells represents the preservation of a normal chromaffin cell characteristic rather than a tumor-induced ectopic phenomenon.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
CRH IS produced at several extrahypothalamic sites. CRH is detectable in the adrenals of a number of species, including humans (1, 2, 3, 4), rodents (5, 6, 7, 8), cows (9, 10, 11), and dogs (12). In dogs, the CRH-producing cells in the adrenals are almost exclusively localized at the outer medullary zone (12). The physiological role of this CRH is unknown. It has been suggested that adrenal CRH may play a systemic role because stimulation of the adrenal splanchnic nerves creates an immunoreactive (IR)-CRH gradient between adrenal vein and periphery (10). However, its low concentration and the presence of the CRH-binding protein should minimize any potential systemic effect. It is much more probable that adrenal CRH acts locally, either on the cortex or the medulla, because specific CRH-binding sites are present in primate (13, 14) and rat adrenals (15). The CRH transcript and IR-CRH have been detected also in some human pheochromocytomas, tumors of adrenal chromaffin cells (2, 3, 16, 17, 18, 19).

In a pilot experiment, we have found that CRH is present in normal rat adrenal chromaffin cells and in the PC12 rat pheochromocytoma cell line, a model for the study of chromaffin cell differentiation and catecholamine production by pheochromocytomas (20, 21). The aim of the present work was to test the hypothesis that the production of CRH by PC12 cells represents the preservation of a normal chromaffin cell characteristic and not a tumor-induced expression of a previously unexpressed gene. To prove this hypothesis, we compared dispersed and cultured normal rat chromaffin cells with PC12 cells in relation to CRH secretion, regulation of its production, and response to exogenous CRH and its antagonist. Specifically, we first measured the basal secretion rate of IR-CRH by both types of chromaffin cells and that after exposure to K+, nicotine, interleukin (IL)-1ß (7, 22, 23, 24, 25), and nerve growth factor (NGF). Subsequently, we characterized the IR-CRH in these cells and their culture media by sieve chromatography and RP-HPLC. Finally, we examined the effect of exogenous CRH and of its antagonist, {alpha} helical CRH ({alpha}hCRH) on basal and nicotine-induced epinephrine secretion from the chromaffin cells and on basal, nicotine-, and NGF-induced dopamine secretion from the PC12 cells. Our results show that CRH is released by both types of cells, its secretion and synthesis seem to be similarly regulated, and it exerts a significant and comparable regulatory effect on the production of catecholamines by both types of chromaffin cells.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Culture of normal rat adrenal chromaffin cells
Rat adrenal chromaffin cells were isolated according to a modification of a previously published method (26). Briefly, adrenal glands obtained from female Sprague-Dawley rats (Charles-Rivers, Milano, Italy) weighing 100–150 g, were removed immediately after death and placed on sterile petri dishes containing HBSS buffer, 50 IU/ml penicillin G, 50 IU/ml streptomycin (GIBCO-BRL Co., Breda, The Netherlands) The surrounding capsular tissue and fat were removed, each adrenal cut in half, the medullary part dissected out, and the medullae were washed in medium, minced gently to smaller fragments, and placed in the dispersion medium containing HBSS buffer, 50 IU/ml penicillin, 50 IU/ml streptomycin, 0.15% collagenase II, 0.125% trypsin, and 2 U/ml DNase I. After a 90-min incubation at 37 C in a shaker, the process was terminated by the addition of FCS. The medium was centrifuged at 500 x g for 10 min. The cells were resuspended in medium containing DMEM/HAM’s F-12 medium, 15 mM HEPES, 10% FCS, 10 mM glutamine, and antibiotics. Cell suspensions at a concentration of 2–3 x 105 cells/ml were layered in transwell plates (Costar Europe LTD, Badhoevedorp, The Netherlands) and left to grow at 5% CO2 incubator, 37 C (Forma Scientific, Marietta, OH).

Culture of PC12 rat pheochromocytoma cells
The PC12 cells were kindly provided by Dr. G. Guroff, Section on Growth Factors, NICHD, NIH, Bethesda, MD, handled as previously described (21). Briefly, PC12 cells were cultured on either flat-bottom wells in 12-well plates of 4.5 cm2 surface area per well (Costar Europe LTD) or on flasks of 75 cm2 surface area at an initial concentration of 1 x 105 cells per cm2. The cells were left to grow in DMEM (GIBCO-BRL Co.), containing 10 mM L-glutamine, 1.5 mM HEPES, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 7.5% horse serum, and 7.5% FCS in an incubator (Forma Scientific) at 5% CO2 and 37 C. Differentiation of PC12 to neuron-like cells followed exposure to 7S NGF (25 ng/ml for 1 week). The 7S NGF was kindly provided by Dr. G. Guroff, Section on Growth Factors, NICHD, NIH, Bethesda, MD.

CRH RIA
Peptides in culture media were concentrated by a C-18 reverse phase column (Sep-Pak, Waters Associates, Milford, MA) after acidification in 2 vol 0.1 N HCI and centrifuged at 1.5 x 103 rpm for 10 min. The supernatants were extracted by activated Sep-Pak cartridges, washed with 20 ml 0.1 N HCI eluted with 3 ml acetonitrile 80%-0.01% HCI, then dried under vacuum (Speed-Vac). The IR-CRH content of the Sep-Pak extracts was assayed by RIA using a rabbit antiserum (Neosystem Labboratoire, Strasbourg, France) raised against human/rat CRH; it does not cross-react with ovine CRH, human ACTH, LHRH, or AVP. The sensitivity of the assay was 1 pg/tube. The intraassay coefficient of variation was 4.4% and the interassay was 6.6%. Results are expressed as picograms of IR-CRH per mg of total cellular protein determined on whole cellular homogenates by the Bradford method (27) using BSA as standard (28).

Sieve chromatography
Pooled culture media and PC12 cell homogenates were acidified in 2 vol 0.1 N HCI, centrifuged at 1 x 105 rpm x 10 min and the supernatant extracted by activated Sep-Pak cartridges, washed with 20 ml 0.1 N HCI, eluted with 3 ml acetonitrile 80%-0.01% HCI, and dried under vacuum (Speed-Vac). The sample was reconstituted in 0.5 ml 10% formic acid containing 0.5% defatted BSA and 6 M urea and chromatographed on Sephadex G-50 (0.9 x 60 cm, bed vol 40 ml, flow rate of 1.5 ml/h, 1-ml fractions collected). Fractions were dried under vacuum and reconstituted for RIA. The G-50 column was calibrated with blue dextran and synthetic human CRH.

RP-HPLC
PC12 cells were homogenized in 5 vol 0.1% trifluoroacetic acid (TFA), centrifuged at 10,000 rpm for 20 min, the supernatant dried under vacuum, reconstituted in 30 µl 25% acetonitrile-0.1% TFA, centrifuged again for 10 min and one third of its supernatant was injected into an HPLC connected to a 0.2 x 30 cm C18 µBondapack column (Waters Associates). A linear gradient program was used, employing a TFA-acetonitrile solvent system (see Fig. 3Go). Solvent A was composed of 20% acetonitrile-0.1% TFA and solvent B of 80% acetonitrile-0.1% TFA. The flow rate was 1 ml/min. Samples of 1 ml were collected. The retention time (Rt) of the IR-CRH extracted from the PC12 cells was determined by RIA after evaporation of the HPLC fractions and reconstitution in RIA medium. After the sample runs, 20 ng diluted synthetic r-CRH and a completely oxidized r-CRH by 5% H2O2 were run and their Rt determined also by RIA.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 3. RP-HPLC analysis of PC12 cell homogenates. The acetonitrile gradient is indicated by the broken line. The first arrow indicates the elution position of synthetic Met(O) r-CRH oxidized by H2O2. The second arrow indicates the elution position of r-CRH. Approximately half of the IR-CRH from PC12 cells was oxidized during the extraction procedures.

 
Measurement of catecholamines
The concentration of the endogenous catecholamines in the culture media was measured as previously described (21). Briefly, samples of 600 µL were aspirated from each well and transferred to tubes containing 100 µL 0.1 N HCl to ensure the stability of the catecholamines (stable in acidic pH). Subsequently, catecholamines were extracted by acetone precipitation. The extracts were then evaporated and reconstituted in 200 µL of the mobile phase of the HPLC. Samples of 25 µL (i.e. one eighth of the initially extracted material) were injected into the RP-HPLC (HP-1090, Hewlett-Packard, Germany) equipped with an electrochemical S100A detector (ESA Inc., Coulochem). The detector was set at +0.45 mV (with respect to an H2/H+ couple reference electrode) and the guard cell at +0.5 mV. The guard and main columns were RP-18, 5-µm particle size (Hewlett-Packard). The size of the main column was 200 x 4.6 mm. The mobile phase was composed of 25 mM NaH2PO4.H2O, 3.2 mM 1-heptane sulfonic acid sodium salt, 0.5 mM EDTA, and 7.5% methanol. The signals were recorded in an analogue digital converter (HP-35900 C, Hewlett-Packard) connected to an HP-1040 computer.

Statistical analysis
The concentration of the IR-CRH in the culture media was normalized per total cellular protein of the resuspended and homogenized cells at the end of each experiment. The secretion of epinephrine and dopamine in the culture media was expressed as either the mean in ng ± SEM of five or more experiments, per well per mg of cell protein or as percent change compared with control wells. Total cellular protein in each well was measured by the Bradford Coomassie Brilliant Blue G250 method (Serva, GmbH & Co, Germany) using BSA as standard (27, 28). For the statistical evaluation of our data, we used ANOVA followed by two multiple comparison tests: the Fisher’s least significant difference and the Newman-Keuls test. For the data expressed as percentages of change over controls, we have used the nonparametric Kruskal-Wallis test for several independent samples.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
IR-CRH was detectable in the media and cellular extracts of both normal rat adrenal chromaffin and of the PC12 rat pheochromocytoma cells. Figure 1Go depicts the basal concentration of IR-CRH in the culture media over a period of 48 h. The determination of IR-CRH was performed in plain test media after removal of the horse and FCS-enriched culture media. The concentration of IR-CRH in the media from early passage PC12 cells (5 and 6) (lower curve) was lower compared with normal chromaffin cells (upper curve). However, it increased with the number of passage becoming, in late passages, higher than that of chromaffin cells. Thus, PC12 cells of passage 17 had two to three times more CRH compared with normal chromaffin cells (see Fig. 5Go), an observation reproduced in multiple experiments. The significance of the positive correlation between PC12 passage and their capacity to produce CRH is unclear, but it may suggest that the capacity to produce CRH is affected by the state of PC12 differentiation, a hypothesis also supported by the NGF-derived data (see below). Figure 1Go also shows that replacement of the culture media stimulates the secretion of CRH, which peaks between 6 and 12 h and subsequently either (a) declines slightly reaching a stable plateaux (in the normal chromaffin cells), or (b) it declines even further to low levels (in the PC12 cells). The latter is a well-documented phenomenon, characteristic of several neoplastic cells, including pheochromocytomas; it results from the production of large quantities of proteases from the tumoral cells (29). Incubation of similar concentrations of standard CRH in PC12-conditioned media produced a similar curve. Based on these data, for the subsequent experiments testing the effect of exogenous CRH, we used aprotinin at 100 kU/ml to protect it from these proteases.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 1. IR-CRH in the media of dispersed normal chromaffin cells (upper curve) and PC12 cells of passage 6 (lower curve). Each point represents the mean + SE of IR-CRH, n = 6.

 


View larger version (33K):
[in this window]
[in a new window]
 
Figure 5. Effect of rh IL-1ß (40 ng/ml for 36 h) on IR-CRH release from normal chromaffin cells (light grey bars) and PC12 cells (white bars). Statistical evaluation as per Fig. 4Go.

 
Figure 2Go depicts the effect of a depolarizing dose of KCl on IR-CRH in the PC12 test media (n = 6). The peak CRH response occurred at 20 min, and it was almost one order of magnitude higher than that of parallel controls (from 18.6 ± 3 to 138 ± 1, n = 12). Similar data were obtained from normal rat chromaffin cells. On sieve chromatography, the apparent molecular weight of IR-CRH in the test media was similar or identical to that of synthetic r-CRH (Fig. 2Go, insert).



View larger version (14K):
[in this window]
[in a new window]
 
Figure 2. Effect of a depolarizing dose of K+ on IR-CRH release from PC12 cells. A similar curve was obtained from normal rat chromaffin cells. Insert, gel filtration chromatography of IR-CRH from pooled PC12 media.

 
Figure 3Go depicts the RP-HPLC chromatographic profile of IR-CRH present in PC12 cellular extracts. A gradient of acetonitrile (CH3CN) was used (indicated by the broken line) in the presence of 0.1 N TNF. The Rt of IR-CRH from the PC12 extracts was identical to that of synthetic r-CRH. On the graph, the first peak represents the oxidized Met(O) CRH (this oxidation takes place during the extraction procedure), whereas the second peak is that of the putative peptide. RP-HPLC chromatography of pooled extracts from 24-h PC12 culture media exhibited the same IR-CRH profile.

Figure 4Go depicts the effect of nicotine on the release of IR-CRH from normal chromaffin (upper panel) and PC12 cells (lower panel). Nicotine stimulated the release of IR-CRH from both types of cells in a dose- and time-dependent manner. The onset of this effect was early, starting within 30 min of the application of nicotine. This finding suggests that, as expected, the stimulatory effect of nicotine mainly involves secretion.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 4. Effect of nicotine at 10-6 M on IR-CRH release from normal chromaffin (upper panel) and PC12 cells (lower panel). The letters identify the pairs compared by multiple comparison tests after ANOVA. Statistical difference between pairs is marked by an (*) if 0.02<P < 0.05 and (**) if P < 0.02.

 
It is now known that IL-1ß stimulates the synthesis of CRH in the parvo cells of the paraventricular hypothalamic nucleus (30). Figure 5Go depicts the effect of IL-1ß, at 40 ng/ml for 36 h, on the rate of IR-CRH accumulation in the test media of normal chromaffin cells (light grey bars) and of PC12 cells (white bars). The onset of the effect of IL-1ß required at least 36 h of exposure, suggesting that it involved mainly synthesis. Indeed, IL-1ß had no statistically significant acute effects on CRH secretion from either type of chromaffin cell. It should be noted that the one order of magnitude difference between the basal (zero exogenous IL-1ß) concentration of IR-CRH in this experiment (PC12 passage 17) compared with the one depicted in Fig. 1Go (PC12 passage 6) illustrates the significance of the number of passage on CRH production.

As expected, exposure of PC12 to 7S NGF (25 ng/ml for 1 week) induced their differentiation to neuron-like cells. The thus differentiated PC12 cells exhibited a highly significant increase in their capacity to produce CRH (as well as catecholamines). Figure 6Go depicts the rate of CRH accumulation in the media of these cells, which was approximately 30 times higher compared with parallel controls (i.e. PC12 cells cultured for the same number of days without NGF). The concentration of IR-CRH in the test media is normalized per milligram of total cellular protein to eliminate a possible, although unlikely, proliferative effect of NGF. The secretion of IR-CRH in terms of cell number is as follows: from normal rat chromaffin cells in culture: 15 ± 2 at 12 h (mean IR-CRH ± SE in picograms per million cells, n = 6), 13 ± 1 at 24 h, 12 ± 1 at 48 h. From PC12 of early passage: 2 ± 0.5 at 12 h, 1 ± 0.1 at 24 h, 1 ± 0.2 at 48 h. From NGF-treated PC12 cells of early passage: 104 ± 13 at 12 h, 60 ± 10 at 24 h, and 58 ± 24 at 48 h. From PC12 cells of late passage: 44 ± 0.4 at 12 h, 85 ± 20 at 24 h, and 15 ± 2 at 48 h.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 6. Differentiation of the PC12 to neuron-like cells induced by 7S NGF (25 ng/ml for 1 week) caused a 30-fold increase in the rate of CRH secretion compared with parallel control PC12 cells cultured for the same number of days without NGF. The concentration of CRH is normalized per milligram of total cellular protein.

 
Short exposures of normal chromaffin and PC12 cells to synthetic CRH did not alter the rate of the secretion of catecholamines. It took 12 h or longer for the stimulatory effect of CRH on catecholamines to take place. This finding suggests that CRH mainly affects catecholamine synthesis, a phenomenon described previously for normal chromaffin cells (13). Thus, the data for the dose response curves were taken from cultures exposed to CRH for 12 h. To protect synthetic CRH from tumor-derived proteases, aprotinin (100 kU/ml) was used. This concentration of aprotinin was sufficient to prevent CRH degradation. Figure 7Go depicts the effect of CRH at 10-6 M over 48 h on epinephrine release from normal chromaffin cells (upper panel), and on dopamine release from PC12 cells (lower panel). Figure 8Go depicts the dose-dependent effect of CRH on the concentration of epinephrine in the test media of normal chromaffin cells (upper panel), and of dopamine of PC12 cells (lower panel). The stimulatory effect of CRH was similar between the two types of chromaffin cells. Indeed, CRH stimulated the secretion of epinephrine from chromaffin cells (upper curve, upper panel), and dopamine from PC12 cells (upper curve, lower panel). {alpha}hCRH at 10-5 M blocked the stimulatory effect of CRH on chromaffin cells (lower curve, upper panel) and partially blocked its effect on PC12 cells (lower curve, lower panel). {alpha}hCRH alone did not have any statistically significant effect on basal or nicotine-induced catecholamine secretion from either type of chromaffin cell.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 7. Effect of CRH at 10-6 M on epinephrine secretion from normal chromaffin cells (upper panel) and dopamine from PC12 cells (lower panel) over 48 h. Statistical evaluation as per Fig. 4Go.

 


View larger version (17K):
[in this window]
[in a new window]
 
Figure 8. Effect of CRH on epinephrine secretion from normal chromaffin cells (upper panel, upper curve) and on dopamine from PC12 cells (lower panel, upper curve). {alpha}hCRH at 10-5 M blocked the stimulatory effect of CRH on epinephrine (upper panel, lower curve) and on dopamine (lower panel, lower curve). Statistical evaluation as per Fig. 4Go.

 
Differentiation of PC12 to neuron-like cells after exposure to 7S NGF (25 ng/ml for 1 week) resulted in an increase of their production of dopamine. Figure 9Go depicts the accumulation of dopamine into the culture media of the neuronally differentiated cells over 12 h. The differentiated cells produced almost 10 times more dopamine compared with PC12 cells exposed only to the NGF vehicle (control cells). The increased rate of dopamine accumulation in the NGF-treated cells was prevented completely by preincubation with the CRH antagonist ahCRH at 10-6 M, suggesting that endogenous CRH may mediate this phenomenon. Synthetic CRH did not affect the production of catecholamines from NGF-differentiated PC12 cells, suggesting that the local CRH receptors were already downregulated.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 9. PC12 cells exposed to NGF for 1 week, differentiated to neuron-like cells. These cells produced 10 times more dopamine (first column) compared with parallel control cell cultured for the same number of days without NGF (second column). Each column represents total IR-CRH released over a period of 12 h. The constant presence of {alpha}hCRH at 10-5 M during the NGF treatment prevented its stimulatory effect (third column).

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Our results indicate that the CRH neuropeptide is produced by both normal rat adrenal chromaffin cells and the widely used PC12 rat pheochromocytoma cell line. Our data supplement previously published results in other species (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12). It now seems that the capacity to produce CRH is a property of normal adrenal chromaffin cells and that the production of CRH by the PC12 cells may represent the preservation of a normal chromaffin cell characteristic rather than a tumor-induced ectopic phenomenon. This hypothesis may be applicable also to human pheochromocytomas. Indeed, our data show that the amount of CRH produced by the normal rat chromaffin cells and the tumoral PC12 cells and their responce to a variety of stimuli was similar or identical, suggesting that the pathway of CRH synthesis remains intact in the PC12 cells.

The release of IR-CRH into the culture media paralleled that of catecholamines, suggesting costorage, a property characteristic of most neural crest-derived cells in which neuropeptides and neurotransmitters are packaged into the same secretory granules (31). The role of adrenomedullary CRH and the physiological significance of its simultaneous release with catecholamines is not known.

IL-1ß stimulates the production of CRH from the parvo cells of the paraventricular hypothalamic nucleus (30). We have found that normal chromaffin cells and the PC12 cell line responded to IL-1ß by an increase of CRH release of late onset, suggesting that, in similarity to hypothalamus, this cytokine affects CRH synthesis rather than secretion.

The concentration of CRH in the normal chromaffin and the PC12 media was in the range of 0.2–0.5 x 10-11 M. This secretion rate suggests that chromaffin cell-derived CRH can not have systemic effects. It is more likely that its effects are confined within the adrenals. Indeed, the calculated in vivo concentration of CRH in the interstitial compartment of an intact adrenal medulla may reach the biologically active levels of 1–2 x 10-10 M, i.e. near the Kd of the CRH receptor.

In the central nervous system, there is a close anatomical proximity between CRH and noradrenergic neurons at the level of locus ceruleus (32, 33). In the rat, CRH stimulates the release of catecholamines from locus ceruleus, as well as from hypothalamus, medial prefrontal cortex, and the hippocampal dentate gyrus in vivo (34, 35, 36, 37). This effect of CRH is blocked by {alpha}hCRH (37). This effect of CRH involves catecholamine synthesis via stimulation of the activity of tyrosine hydroxylase, the rate limiting enzyme (38, 39). All available evidence indicates that CRH plays a similar role in the adrenal medulla because the latter also contains CRH receptors (13, 14). Our data support this hypothesis, demonstrating a dose-depended stimulatory effect of CRH on the production of catecholamines from both normal and PC12 tumoral rat adrenal chromaffin cells. The apparent preservation, by PC12 cells, of the CRH-mediated effect on catecholamine synthesis may suggest that CRH is an important component of the adrenomedullary physiology.

A well-documented characteristic of the PC12 line is its differentiation to neuron-like cells after exposure to NGF for 1 week. We have found that the neuron-like PC12 cells secreted 10 times more catecholamines compared with parallel controls and thirty times more CRH. Our finding is in complete agreement with previously published data from primary cultures of human pheochromocytomas, in which NGF increased the concentration of CRH mRNA by 10-fold (19). The stimulatory effect of NGF on the capacity of PC12 cells to produce catecholamines seems to involve CRH because exposure of PC12 cells to the CRH antagonist, ahCRH, during the incubation with NGF completely abolished the NGF-mediated stimulatory effect. It is thus possible that the following sequence of events takes place: the NGF-induced differentiation of PC12 cells causes an increase in their CRH-producing capacity; the high levels of PC12-derived CRH act in a paracrine manner and stimulate the synthesis of tyrosine hydroxylase, which stimulates the synthesis of catecholamines. Blockage of the endogenous CRH paracrine effect prevents the stimulatory effect of NGF.

Exogenous synthetic CRH did not affect the production of catecholamines from the NGF-differentiated PC12 cells, in contrast to the NGF-unexposed PC12 cells. This finding suggests that either the PC12 CRH receptors were already maximally activated and possibly downregulated or the production of catecholamines was already at its highest possible level as a consequence of the NGF-induced differentiation.

In conclusion, our data suggest that the production of CRH by PC12 cells represents the preservation of a normal chromaffin cell characteristic rather than a tumor-induced ectopic phenomenon. From a clinical point of view, our findings may be of value in some inoperable pheochromocytomas in which the production of catecholamines could be inhibited by the new nonpeptide CRH antagonists.


    Acknowledgments
 
We would like to thank Drs. Kouvarakis and Stephanou of the School of Chemistry, University of Crete, for their help with the RP-HPLC.


    Footnotes
 
1 This work was supported by the Greek Ministry of Industry, Energy, and Technology (Grant: 91 ED 10), the PEPAGNH University Hospital of Iraklion, Crete, and Medicon Hellas. Back

Received June 10, 1996.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Suda T, Tomori N, Tozawa F, Mouri T, Demura H, Shizume K 1984 Distribution and characterization of immunoreactive corticotropin-releasing factor in human tissues. J Clin Endocrinol Metab 59:861–867[Abstract/Free Full Text]
  2. Suda T, Tomori N, Yajima F, Odagiri E, Demura H, Shizume K 1986 Characterization of immunoreactive corticotropin and corticotropin-releasing factor in human adrenal and ovarian tumors. Acta Endocrinol (Copenh) 111:546–552[Abstract/Free Full Text]
  3. Nicholson WE, DeCherney GS, Jackson RV, Orth DN 1987 Pituitary and hypothalamic hormones in normal and neoplastic adrenal medulla: biologically active corticotropin-releasing hormone and corticotropin. Regul Pept 18:173–188[CrossRef][Medline]
  4. Usui T, Nakai Y, Tsukada T, Jingami H, Takahashi H, Fukata J, Imura H 1988 Expression of the adrenocorticotropin-releasing hormone precursor gene in placenta and other nonhypothalamic tissues in man. Mol Endocrinol 2:871–875[Abstract/Free Full Text]
  5. Merchenthaler I 1984 Corticotropin-releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides 5:53–69
  6. Bagdy G, Calogero AE, Szemeredi K, Chrousos GP, Gold PW 1990 Effects of cortisol treatment on brain and adrenal corticotropin-releasing hormone (CRH) content and other parameters regulated by CRH. Regul Pept 31:83–92[CrossRef][Medline]
  7. Naito Y, Fukata J, Nakaishi S, Nakai Y, Hirai Y, Tamai S, Mori K, Imura H 1990 Chronic effects of interleukin-1 on hypothalamus, pituitary and adrenal glands in rat. Neuroendocrinology 51:637–641[Medline]
  8. Mazzocchi G, Malendowicz LK, Markowska A, Nussdorfer GG 1994 Effect of hypophysectomy on corticotropin-releasing hormone and adrenocorticotropin immunoreactivities in the rat adrenal gland. Mol Cell Neurosci 5:345–349[CrossRef][Medline]
  9. Hashimoto K, Murakami K, Hattori T, Niimi M, Fujimo K, Ota Z 1984 Corticotropin-releasing factor (CRF)-like immunoreactivity in the adrenal medulla. Peptides 5:707–712[CrossRef][Medline]
  10. Edwards AV, Jones CT 1988 Secretion of corticotropin releasing factor from the adrenal during splachnic nerve stimulation in conscious calves. J Physiol (Lond) 400:89–100[Abstract/Free Full Text]
  11. Minamino N, Uehara A, Arimura A 1988 Biological and immunological characterization of corticotropin-releasing activity in bovine adrenal medulla. Peptides 9:37–45[CrossRef][Medline]
  12. Bruhn TO, Engeland WC, Anthony ELP, Gann DS, Jackson IDM 1987 Corticotropin-releasing factor in the dog adrenal medulla is secreted in response to hemorrhage. Endocrinology 120:25–33[Abstract/Free Full Text]
  13. Udelsman R, Harwood JP, Millan MA, Chrousos GP, Golstein DS, Zimlichman R, Catt KJ, Aguilera G 1986 Functional corticotropin-releasing factor receptors in the primate peripheral sympathetic nervous system. Nature 6049:147–150
  14. Aguilera G, Millan MA, Hauger RL, Catt KJ 1987 Corticotropin-releasing factor receptors: distribution and regulation in brain, pituitary and peripheral tissues. Ann NY Acad Sci 512:48–66[Medline]
  15. Dave JR, Eiden LE, Eskay RL 1985 Corticotropin-releasing factor binding to peripheral tissue and activation of the adenylate cyclase-adenosine 3', 5'-monophosphate system. Endocrinology 116:2152–2159[Abstract/Free Full Text]
  16. Sasaki A, Yumita S, Kimura S, Miura Y, Yoshinaga K 1990 Immunoreactive corticotropin-releasing hormone, somatostatin, and peptide histidine methionine are present in adrenal pheochromocytomas, but not in extra-adrenal pheochromocytoma. J Clin Endocrinol Metab 70:996–999[Abstract/Free Full Text]
  17. O’Brien T, Young WF, Davila DG, Scheithauer BW, Kovacs K, Hovath E, Vale W, van Heerden JA 1992 Cushing’s syndrome associated with ectopic production of corticotropin-releasing hormone, corticotropin and vasopressin by pheochromocytoma. Clin Endocrinol (Oxf) 37:460–467[Medline]
  18. Tsuchihashi T, Yamaguchi K, Abe K, Yanaihara N, Saito S 1992 Production of immunoreactive corticotropin-releasing hormone in various neuroendocrine tumors. Jpn J Clin Oncol 22:232–237
  19. Liu J, Heikkila P, Voutilainen R, Karonen SL, Kahri AI 1994 Pheochromocytoma expressing adrenocorticotropin and corticotropin-releasing hormone; regulation by glucocorticoids and nerve growth factor. Eur J Endocrinol 131:221–228[Abstract/Free Full Text]
  20. Kittner B, Brautigan M, Herken H 1987 PC12 cells: a model system for studying drug effects on dopamine synthesis and release. Arch Int Pharmacodyn Ther 286:181–194[Medline]
  21. Venihaki M, Gravanis A, Margioris AN 1996 Opioids inhibit dopamine secretion from PC12 rat pheochromocytoma cells in a naloxone-reversible manner. Life Sci 58:75–82[CrossRef][Medline]
  22. Schultzberg M, Andersson C, Unden A, Troye-Blomberg M, Svenson SB, Bartfai T 1989 Interleukin-1 in adrenal chromaffin cells. Neuroscience 30:805–810[CrossRef][Medline]
  23. Alheim K, Andersson C, Tingsborg S, Ziolkowska M, Schultzberg M, Bartfai T 1991 Interleukin-1 expression is inducible by nerve growth factor in PC12 pheochromocytoma cells. Proc Natl Acad Sci USA 88:9302–9306[Abstract/Free Full Text]
  24. Li XM, Juorio AV, Boulton AA 1994 Induction of aromatic L-amino acid decarboxylase mRNA by interleukin-1 ß and prostaglandin E2 in PC12 cells. Neurochem Res 19:591–595[CrossRef][Medline]
  25. Yanagihara N, Minami K, Shirakawa F, Uezono Y, Kobayashi H, Eto S, Izumi F 1994 Stimulatory effect of IL-1 ß on catecholamine secretion from cultured bovine adrenal medullary cells. Biochem Biophys Res Commun 198:81–87[CrossRef][Medline]
  26. Livett BG 1984 Adrenal medullary chromaffin cells in vitro. Physiol Rev 64:1103–1161[Free Full Text]
  27. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254[CrossRef][Medline]
  28. Hatzoglou A, Prekezes J, Tsami M, Castanas E 1992 Protein measurement of particulate and solubilized ovine liver membranes. Ann Clin Biochem 29:659–662
  29. Konoshita T, Gasc JM, Villard E, Takeda R, Seidah NG, Corvol P, Pinet F 1994 Expression of PC2 and PC1/PC3 in human pheochromocytomas. Mol Cell Endocrinol 99:307–314[CrossRef][Medline]
  30. Suda T, Tozawa F, Ushiyama T, Sumitomo T, Yamada M, Demura H 1990 Interleukin-1 stimulates corticotropin-releasing factor gene expression in rat hypothalamus. Endocrinology 126:1223–1228[Abstract/Free Full Text]
  31. Schallin M, Dagerlind A, Stieg P, Lindquist C, Hokfelt T 1991 Colocalization of neurotransmitters analyzed by in situ hybridization. Eur Neuropsycho- pharmacol 1:173–176
  32. Valentino RJ, Page ME, Van Bockstaele E, Aston-Jones G 1992 Corticotropin-releasing factor innervation of the locus-coeruleus region: distribution of fibers and source of input. Neuroscience 48:689–705[CrossRef][Medline]
  33. Austin MC, Rice PM, Mann JJ, Arango V 1995 Localization of corticotropin-releasing hormone in the locus coeruleus and pedunculopontine tegmental nucleus: an immunocytochemical and in situ hybridization study. Neuroscience 64:713–727[CrossRef][Medline]
  34. Emoto H, Yokoo H, Yoshida M, Tanaka M 1993 Corticotropin-releasing factor enhances noradrenaline release in the rat hypothalamus assessed by intracerebral microdialysis. Brain Res 601:286–289[CrossRef][Medline]
  35. Lavicky J, Dunn AJ 1993 Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J Neurochem 60:602–612[CrossRef][Medline]
  36. Lee EHY, Chang SY, Chen AYJ 1994 CRH facilitates NE release from the hippocampus: a microdialysis study. Neurosci Res 19:327–330[CrossRef][Medline]
  37. Smagin GN, Swirgiel AH, Dunn AJ 1995 Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex. Brain Res Bull 36:71–76[CrossRef][Medline]
  38. Olianas MC, Onali P 1988 Corticotropin-releasing factor activates tyrosine hydroxylase in rat and mouse striatal homogenates. Eur J Pharmacol 150:389–392[CrossRef][Medline]
  39. Posener JA, Schidkraut JJ, Williams GH, Gleason RE, Salomon MS, Mecheri G, Schatzberg AF 1994 Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man. Biol Psychiatry 36:616–621[CrossRef][Medline]



This article has been cited by other articles:


Home page
EndocrinologyHome page
E. Dermitzaki, C. Tsatsanis, V. Minas, E. Chatzaki, I. Charalampopoulos, M. Venihaki, A. Androulidaki, M. Lambropoulou, J. Spiess, E. Michalodimitrakis, et al.
Corticotropin-Releasing Factor (CRF) and the Urocortins Differentially Regulate Catecholamine Secretion in Human and Rat Adrenals, in a CRF Receptor Type-Specific Manner
Endocrinology, April 1, 2007; 148(4): 1524 - 1538.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Charalampopoulos, C. Tsatsanis, E. Dermitzaki, V.-I. Alexaki, E. Castanas, A. N. Margioris, and A. Gravanis
Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins
PNAS, May 25, 2004; 101(21): 8209 - 8214.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. Agelaki, C. Tsatsanis, A. Gravanis, and A. N. Margioris
Corticotropin-Releasing Hormone Augments Proinflammatory Cytokine Production from Macrophages In Vitro and in Lipopolysaccharide-Induced Endotoxin Shock in Mice
Infect. Immun., November 1, 2002; 70(11): 6068 - 6074.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Dermitzaki, C. Tsatsanis, A. Gravanis, and A. N. Margioris
Corticotropin-releasing Hormone Induces Fas Ligand Production and Apoptosis in PC12 Cells via Activation of p38 Mitogen-activated Protein Kinase
J. Biol. Chem., March 29, 2002; 277(14): 12280 - 12287.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. Preil, M. B. Muller, A. Gesing, J. M. H. M. Reul, I. Sillaber, M. M. van Gaalen, J. Landgrebe, F. Holsboer, M. Stenzel-Poore, and W. Wurst
Regulation of the Hypothalamic-Pituitary-Adrenocortical System in Mice Deficient for CRH Receptors 1 and 2
Endocrinology, November 1, 2001; 142(11): 4946 - 4955.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
K.-H. Jeong, L. Jacobson, K. Pacak, E. P. Widmaier, D. S. Goldstein, and J. A. Majzoub
Impaired Basal and Restraint-Induced Epinephrine Secretion in Corticotropin-Releasing Hormone- Deficient Mice
Endocrinology, March 1, 2000; 141(3): 1142 - 1150.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Ehrhart-Bornstein, J. P. Hinson, S. R. Bornstein, W. A. Scherbaum, and G. P. Vinson
Intraadrenal Interactions in the Regulation of Adrenocortical Steroidogenesis
Endocr. Rev., April 1, 1998; 19(2): 101 - 143.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
M. Venihaki, K. Ain, E. Dermitzaki, A. Gravanis, and A. N. Margioris
KAT45, a Noradrenergic Human Pheochromocytoma Cell Line Producing Corticotropin-Releasing Hormone
Endocrinology, February 1, 1998; 139(2): 713 - 722.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. A. Seth and J. A. Majzoub
Repressor Element Silencing Transcription Factor/Neuron-restrictive Silencing Factor (REST/NRSF) Can Act as an Enhancer as Well as a Repressor of Corticotropin-releasing Hormone Gene Transcription
J. Biol. Chem., April 20, 2001; 276(17): 13917 - 13923.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Venihaki, M.
Right arrow Articles by Margioris, A. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Venihaki, M.
Right arrow Articles by Margioris, A. N.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals